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Introduction
Patients with severe gastrointestinal bleeding (GIB) who are he-
modynamically unstable are usually admitted to an intensive
care unit (ICU) [1] for stabilization and possible endoscopic
management. By definition, these patients are usually hemody-
namically unstable and are at increased risk of endoscopic com-
plications during evaluation [2–6]. Hematemesis localizes
bleeding to within reach of a gastroscope. In patients with non-
hematemesis GIB, the presence of melena or hematochezia has
little localizing value [6], leading to what has become a tradi-
tional approach of upper endoscopy followed by colonoscopy
and other procedures if 1 of those 2 are not diagnostic [7].
However, the yield of conventional endoscopic procedures in
this context is known to be low. An early diagnostic/endoscopic
approach is thought to have higher diagnostic yield in some
studies, yet this advantage needs to be balanced with risk of
endoscopic complications [8–11].
Video capsule endoscopy (VCE) is a minimally invasive tool
that can visualize the gastrointestinal tract from esophagus to
the right colon without the need for sedation or preparation.
We hypothesize that VCE could serve as an alternative to the
traditional approach to GIB in an acutely unstable or high-risk
patient. VCE has been investigated as a triaging tool in the
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ABSTRACT
Background and study aims Video capsule endoscopy
(VCE) is a minimally invasive tool that helps visualize the
gastrointestinal tract from the esophagus to the right colon
without the need for sedation or preparation. VCE is safe
with very few contraindications. However, its role and safe-
ty profile in the intensive care unit (ICU) population have
not been reported. The aim of this study is to evaluate the
safety, efficacy, and feasibility of VCE use in ICU patients.
Patients and methods We conducted a single-center ret-
rospective observational study of patients who underwent
VCE for evaluation of obscure overt gastrointestinal bleed-
ing in the ICU between 2008 and 2016.
Results This study included 48 patients who were admit-
ted to the UMass Memorial Medical Center ICUs for gastro-
intestinal bleeding. VCE was successfully completed in 43/
48 (90%) patients. The entire length of small bowel could
be evaluated in 75% and the source of bleeding was identi-
fied in 44% of the patients. The most commonly identified
source of bleeding included small bowel angioectasias,
duodenal erosions/ulcers, and small bowel polyps. No ma-
jor complications could be attributed to the VCE. Only 1
capsule was retained after 2 wk; however, there was no in-
cidence of bowel obstruction, perforation, or capsule as-
piration.
Conclusions This observational retrospective study de-
monstrates that VCE may be a safe, feasible, and effective
diagnostic tool in evaluation of gastrointestinal bleeding in
the ICU population with few complications. VCE may be a
safe diagnostic prelude and be a guide to the correct thera-
peutic procedure if needed, in the context of patients who
are seriously ill.
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emergency room to determine the population of patients who
would benefit from additional diagnostic and therapeutic inter-
ventions [12]. However, before the utility of VCE as first-line
evaluation of GIB in ICU patients can be established, the safety
and efficacy of this technique in ICU patients need to be eval-
uated further. We therefore investigated the safety and efficacy
of VCE use in the ICU in a retrospective case series of patients
admitted to the ICU with obscure overt GIB. To our knowledge,
there are no prior studies that specifically evaluated the role
and safety profile of VCE in the ICU population for evaluation
of GIB.
Patients and methods
We conducted a single-center retrospective observational
study (case-series) of patients who underwent VCE for evaluati-
on of obscure overt GIB in our medical, cardiac, and surgical
ICUs between 2008 and 2016 at UMass Memorial Medical Cen-
ter, a large tertiary referral center in central Massachusetts. In-
clusion criteria included age more than 18 y, a diagnosis of GIB
during that admission, and VCE during an ICU stay. Patients
were identified through billing codes, and data collected in-
cluded patients’ demographics, comorbidities, VCE results, ad-
ditional diagnostic/therapeutic procedures, and laboratory
data. Standard descriptive statistics were used for demographic
data, VCE findings, and complications using Microsoft Excel
2007 (Microsoft, Redmond, WA, USA). Additionally, we used
Student’s t-test for comparing continuous variables, and chi-
squared test was used for binary variables. The patients were
investigated using either the M2A or PillCam SB2 capsules (Gi-
venImaging, Jocqneam, Israel). The capsules were read on a
workstation using Rapid software versions 3 to 8. All VCE ima-
ges were read by expert endoscopists with many years of ex-
perience in interpreting VCEs. All patients had been screened
for contraindications of VCE including but not limited to history
of bowel obstruction. In a few patients with high risk of gastric
retention (e. g., prior history) or evidence of retention on the
real-time viewer, a dose of intravenous metoclopramide or ery-
thromycin was administered before or during the capsule
study. VCE was deemed successful if the entire length of the
small bowel could be evaluated or if significant length of the
small bowel was evaluated without significant device malfunc-
tion, missing frames, or gastric retention. The retrospective
chart review was approved by the UMass Memorial Institutional
Review Board.
Results
This study included 48 patients who were admitted to the ICU
for GIB and who had negative esophagogastroduodenoscopy
(EGD) and in many cases colonoscopy (69%) and were categor-
ized as having obscure overt GIB on further investigation. Aver-
age age of patients was 70 ± 16.5 y with 58% male (▶Table 1).
The majority of patients (92%) were Caucasian. More than half
(56%) were on mono or dual antiplatelet therapy, and 31% were
anticoagulated. About one-fifth of patients (19%) had interna-
tional normalized ratio (INR) > 3, and 29% required 2 L or more
▶ Table 1 Demographics.
n (%)
Male 28 (58)
Female 20 (42)
Age (y) 70.4 ± 16.5
BMI 28.3 ± 7.5
Caucasian 44 (92)
Current smoker 13 (27)
Former smoker 26 (54)
Alcohol use 15 (31)
NSAIDs use 5 (10)
Aspirin alone 22 (46)
Dual antiplatelet therapy 5 (10)
Anticoagulated 15 (31)
Presenting symptom
Hematemesis 6 (13)
Hematochezia 15 (31)
Melena 23 (48)
Anemia 4 (8)
Comorbidities
Coronary artery disease 28 (58)
Recent MI 4 (8)
COPD 11 (23)
Pneumonia 8 (17)
Severe aortic stenosis 6 (13)
CHF 13 (27)
ESRD 6 (13)
Cirrhosis 7 (15)
History of IBD 0 (0)
Prior abdominal surgeries 23 (48)
History of small bowel obstruction 0 (0)
INR >3 9 (19)
Hypoxia (> 2 L NC) 14 (29)
Vasopressors required 3 (6)
Need for transfusion 45 (94)
Lowest HGB (average) 6.39 ± 1.14
Lowest HGB (range) 3.8 –8.5
Units of blood transfused 5.9 ± 4.8
BMI: body mass index; COPD: chronic obstructive pulmonary disease; CHF:
congestive heart failure; ESRD: end-stage renal disease; IBD: inflammatory
bowel disease; MI: myocardial infarction; NSAID: nonsteroidal anti-inflam-
matory drug; HGB: hemoglobin; NC: nasal canula
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of supplemental oxygen. Three patients required vasopressor
support for hypotension. Twenty-three patients (48%) initially
presented with melena, 15 (31%) with hematochezia, and 6
(13%) with hematemesis. The most common underlying co-
morbidities included coronary artery disease, congestive heart
failure, and chronic obstructive pulmonary disease. Nearly half
of patients (48%) had history of intra-abdominal surgery, but
none had history of prior small bowel obstruction, inflamma-
tory bowel disease, or fistulas. The mean lowest hemoglobin
was 6.39 ± 1.14mg/dL (range: 3.8–8.5mg/dL) on or within 2d
of admission. Almost all patients 45 (94%) required blood
transfusions with a mean of 5.8 ± 4.8 units transfused. Transfu-
sion requirements were higher in patients whose bleeding
source could be identified as compared to those with unidenti-
fied source (7.9 ± 5.7 vs. 4.3 ± 4.8 units transfused, P<0.01).
The mean lengths of hospital and ICU stays were 10.4 ± 9.6 d
and 5.5 ± 3.6d, respectively.
Most patients 44 /48 (92%) had EGD within 24h of admis-
sion. Two patients had prior negative EGDs within the past 30
d, and 1 patient had EGD at day 8 of admission due to presenta-
tion with hematochezia on day 1 and repeat bleeding on day 7.
Average time to colonoscopy was 1.9 ± 0.9 d in the two-thirds
of patients who underwent this procedure (▶Table2). One pa-
tient with prior history of small bowel bleeding underwent VCE
as first-line evaluation of GIB. Sixteen patients (33%) under-
went VCE as second-line evaluation. The remainder of patients
underwent VCE as third- or fourth-line evaluation for obscure
overt GIB. VCE was successfully completed in 43 /48 (90%) pa-
tients. The majority of capsules were swallowed by the patient
(75%) while the other 25% were placed endoscopically via EGD,
most commonly during negative EGD as the next step in the pa-
tient’s evaluation (▶Table 2). The entire length of small bowel
could be evaluated in 36/48 (75%). The source of bleeding was
identified in 21/48 (44%) patients. However, the source was
identified more commonly when VCE was performed within
48 h of suspected bleeding (63% within 48h vs. 31% with VCE
after 48h, P=0.03). The most commonly identified source of
bleeding included small bowel angioectasias, duodenal ero-
sions/ulcers, and small bowel polyps. The most commonly
identified incidental lesions in the small bowel included an-
gioectasias (nonbleeding and no stigmata of recent bleeding,
portal hypertensive gastropathy/small bowel varices, and ero-
sions. Additional diagnostic interventions (tagged Red Blood
Cell scan, angiography, and deep enteroscopy) was performed
in 17% of patients while 23% required additional therapeutic
interventions.
No major complications could be attributed to the VCE. Only
1 capsule was retained on abdominal imaging after 2wk; how-
ever, there was no incidence of bowel obstruction, perforation,
or capsule aspiration (▶Table 3). Two additional capsules did
not pass through the stomach to enter the small bowel within
the 8h of recorded images but were excreted on follow-up ima-
ging within 2wk. Two earlier studies also included missing
frames or poor image quality within the small bowel, which lim-
ited the interpretation of the small bowel images.
Discussion
This retrospective case series demonstrates that VCE may be a
safe, feasible, and effective diagnostic tool in the evaluation of
obscure overt GIB in the critically ill ICU population. The overall
success rate of the procedure was 90%, with the source of
bleeding identified in nearly half of the patients. Almost all pa-
tients in this study had obscure overt GIB and were previously
evaluated via other modalities. There were no major complica-
tions attributed to the VCE.
▶ Table 2 Outcomes.
n (%)
Successful completion of VCE 43 (90)
Entire small bowel visualized 36 (75)
Anatomic source of bleeding identified 21 (44)
▪ VCE within 48h 12/19 (63)
▪ VCE after 48h 9/29 (31)
▪ p-value 0.03
Actively bleeding lesions 9 (19)
Common sources of bleeding identified
Angioectasias 10 (21)
Small intestinal erosions/ulcers 2 (4)
Small bowel polyps 2 (4)
Portal hypertensive gastropathy 2 (4)
Other 5 (11)
Most common incidental findings
Angioectasias (not clear source of bleed) 7 (15)
Portal hypertensive gastropathy / small intestinal
varices 4 (8)
Erosions 2 (4)
Mode of capsule delivery
Swallowed capsule 36 (75)
Endoscopically placed 12 (25)
Timing of initial diagnostic procedures
EGD within 24 h 44 (92)
Prior EGD within 30d 2 (4)
Colonoscopies during the same admission 33 (69)
Days to colonoscopy (d) 1.9 ± 0.9
Capsule as first-line 1 (2)
Days to VCE (d) 3.47 ± 2.3
Need for additional procedures 19 (40)
Diagnostic 8 (17)
Therapeutic 11 (23)
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While the current study does not address the utility of VCE as
a first-line diagnostic tool for evaluation of GIB, as a minimally
invasive tool, VCE may be a safe diagnostic alternative to stand-
ard endoscopic procedures in patients at risk for significant
complications from the more invasive procedures, such as
those with elevated INR, hypoxemia, or recent myocardial in-
farction [3]. This study demonstrates that VCE is safe in the
most critically ill patients with obscure overt GIB who do not
otherwise have other major contraindications to VCE. However,
the role of VCE as the first-line diagnostic modality in this set-
ting needs to be evaluated further. Inpatient data shows the
earlier VCE is used the better the diagnostic yield [8]. This ob-
servation is supported by similar findings in the current study
as patients who underwent VCE within 48h of admission had
twice the likelihood of bleeding source identification. Larger
prospective studies, particularly with early deployment, are
necessary to further evaluate the safety and efficacy of this
tool in these settings.
Newer video capsule models allow live visualization of the
upper gastrointestinal tract in real time to determine the pres-
ence of active bleeding in the esophagus or stomach and con-
firm passage of capsule into the small intestine. This may help
stratify high-risk patients regarding urgency of more definite
therapeutic interventions while offering additional diagnostic
information regarding possible sources of bleeding in the small
intestine or presence of blood in the right colon. This can, in
turn, potentially minimize the number of invasive procedures,
decrease the length of hospitalization, and minimize complica-
tions in the critically ill patients.
In our cohort, we observed a few cases of gastric retention of
the capsule and delayed transit. Other published and unpub-
lished studies confirm the occurrence of delayed transit in
bed-ridden patients, which are common in the ICU setting. Sev-
eral medications including opioids, commonly used in the ICU,
may also alter gut motility and lead to delayed gastric empty-
ing. The only other study of VCE in ICU patients, to our knowl-
edge, investigated transit time of the VCE in a small cohort of
ICU patients [13]. While this study was not able to show a sta-
tistically significant difference in transit time between ICU pa-
tients compared to ambulatory patients (most likely due to the
very small sample size), there was a large degree of variability in
transit times in the critically ill population. In our practice, we
have most recently developed an algorithm for passage into
the small intestine for swallowed capsules at about an hour
after capsule ingestion. If the capsule is not in the small intes-
tine at that point, we have used prokinetic agents such as me-
toclopramide or erythromycin with good success. This increas-
es the yield of VCE in such select patients.
Another rare technical difficulty was missing frames or poor
image quality in 2 (4%) of our earlier patients. This is most likely
due to electrical interference from nearby devices, distance
from the receiver, or the patient’s excessive movement. Newer
devices with higher-quality signals and images have mostly re-
solved these issues in our most recent cohorts of ICU and non-
ICU patients. However, wireless interference from ventricular
assist devices on image quality of VCE continues to remain a
limitation reported in the literature [14].
The main limitations of this study include the small sample
size and the limitations of the retrospective design. The sample
size is limited by the number of VCEs already performed at our
institution, but to our knowledge, this is the largest cohort of
VCEs studied in the ICU setting. A prospective design will in-
crease the power of the study and make the study more gener-
alizable. The retrospective design also adds its limitations as
there is no control arm and neither the patient nor the clini-
cians are blinded. In addition, this study by its nature is self-se-
lected for patients with obscure GIB. Therefore, further larger
prospective studies are necessary before generalizing the result
to the general ICU population with GIB. Other limitations may
include variation in patient acuity and severity of disease. Our
center is a large tertiary/quaternary with high-acuity patients,
but further studies may help generalize the result to smaller
community sites.
In summary, VCE is safe for use in ICU patients and may be
useful in patients with GIB in detecting the site of active bleed-
ing and providing guidance for the most appropriate therapeu-
tic procedure, if needed.
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